Amgen (XTER:AMG) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:AMG Amgen Inc XTER:AMG
93 GF Score
Price €350.95
GF Value €317.15
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Amgen Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Amgen  (XTER:AMG) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Amgen Cyclically Adjusted PB Ratio Related Terms


Amgen Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Amgen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cyclically Adjusted PB Ratio Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.15 8.54 9.82 9.65 13.49

Amgen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.81 11.20 13.49 14.77 15.58

XTER:AMG vs GILD, PFE, BMY: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PB Ratio falls into.


XTER:AMG
93GF Score
Amgen Inc XTER:AMG
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Amgen's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Amgen's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=18.649/333.9520*333.9520
=18.649

Current CPI (Jun. 2026) = 333.9520.

Amgen Quarterly Data

Book Value per Share CPI Adj_Book
201609 36.814 241.428 50.922
201612 38.376 241.432 53.082
201703 38.915 243.801 53.305
201706 38.638 244.955 52.676
201709 37.215 246.819 50.353
201712 29.533 246.524 40.007
201803 19.009 249.554 25.438
201806 19.664 251.989 26.060
201809 19.199 252.439 25.398
201812 17.452 251.233 23.198
201903 15.603 254.202 20.498
201906 15.866 256.143 20.686
201909 16.642 256.759 21.645
201912 14.720 256.974 19.129
202003 14.599 258.115 18.888
202006 16.141 257.797 20.909
202009 15.945 260.280 20.458
202012 13.374 260.474 17.147
202103 13.629 264.877 17.183
202106 12.017 271.696 14.771
202109 12.362 274.310 15.050
202112 10.621 278.802 12.722
202203 1.557 287.504 1.809
202206 4.278 296.311 4.821
202209 6.916 296.808 7.782
202212 6.472 296.797 7.282
202303 9.349 301.836 10.344
202306 11.701 305.109 12.807
202309 13.406 307.789 14.546
202312 10.674 306.746 11.621
202403 8.621 312.332 9.218
202406 10.250 314.175 10.895
202409 12.617 315.301 13.363
202412 10.452 315.605 11.060
202503 10.679 319.799 11.152
202506 11.964 322.561 12.386
202509 15.219 324.800 15.648
202512 13.723 324.054 14.142
202603 14.729 330.213 14.896
202606 18.649 333.952 18.649

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Amgen (XTER:AMG) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €350.95 is trading 10.7% above its estimated GF Value™ of €317.15. GuruFocus considers Amgen to be Modestly Overvalued.

Key valuation signals for XTER:AMG:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €317.15 vs. price of €350.95 (10.7% above fair value)
  • GF Score™: 93/100 with 7 warning signs

No single metric tells the full story. See the XTER:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
93GF Score

Get the complete analysis for XTER:AMG

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€350.95
Price
€317.15
GF Value